

Supplementary Table 2: Selected active clinical trials evaluating checkpoint blockade in pancreatic cancer

Immune modulator	Class	Target	Co-treatment	n	Phase	Est. primary completion date	ClinicalTrials.gov Identifier
Ipilimumab	ant-mAb	CTLA-4	Gemcitabine	21	Ib	Apr. 2017	NCT01473940*
Nivolumab	ant-mAb	PD-1	Temsirolimus Irinotecan, capecitabine	49	I/II	Apr. 2018	NCT02423954*
Nivolumab	ant-mAb	PD-1	Vaccine (GVAX, CRS-207) Cyclophosphamide	96	II	Jan. 2019	NCT02243371*
Nivolumab	ant-mAb	PD-1	-	1150	I/II	Dec. 2018	NCT01928394*
Ipilimumab	ant-mAb	CTLA-4	-	-	-	-	-
Pembrolizumab	ant-mAb	PD-1	-	477	I	Apr. 2018	NCT02054806*
Pembrolizumab	ant-mAb	PD-1	Bruton Tyrosine kinase inhibitor (ACP-196)	73	II	Sep. 2017	NCT02362048*
Pembrolizumab	ant-mAb	PD-1	MVA-p53 Vaccine	19	I	Apr. 2018	NCT02432963*
Atezolizumab	ant-mAb	PD-L1	-	661	I	May 2018	NCT01375842*
Durvalumab	ant-mAb	PD-L1	-	1022	I/II	Jun. 2017	NCT01693562*
Durvalumab	ant-mAb	PD-L1	-	64	II	Mar. 2018	NCT02527434*
Tremelimumab	ant-mAb	CTLA-4	-	-	-	-	-
Durvalumab	ant-mAb	PD-L1	Anti-CCR4 mAb (Mogamulizumab)	64	I	May 2018	NCT02301130*
Tremelimumab	ant-mAb	CTLA-4	-	-	-	-	-
Durvalumab	ant-mAb	PD-L1	-	NA	II	Dec. 2017	NCT02669914*
Nivolumab	ant-mAb	PD-1	Vaccine (GVAX) Cyclophosphamide	50	I/II	Feb. 2018	NCT02451982
Durvalumab	ant-mAb	PD-L1	Radiation	36	Ib	Feb. 2019	NCT02868632
Tremelimumab	ant-mAb	CTLA-4	-	-	-	-	-
Nivolumab	ant-mAb	PD-1	Radiation	80	II	Nov. 2018	NCT02866383
Ipilimumab	ant-mAb	CTLA-4	-	-	-	-	-
Durvalumab	ant-mAb	PD-L1	Radiation	60	I	Apr. 2018	NCT02311361
Tremelimumab	ant-mAb	CTLA-4	-	-	-	-	-
Pembrolizumab	ant-mAb	PD-1	Radiation + capecitabine	56	I/II	Jun. 2019	NCT02305186
Nivolumab	ant-mAb	PD-1	Nab-Paclitaxel, gemcitabine	138	I	Oct. 2018	NCT02309177
Pembrolizumab	ant-mAb	PD-1	CXCL12 inactivation (olaptosed pegol)	20	I/II	Mar. 2020	NCT03168139

LY3300054	ant-mAb	PD-L1	Anti-VEGFR2 mAb (Ramucirumab) CDK inhibition (Abemaciclib) MET inhibition (Merestinib)	115	Ia/Ib	Jul. 2019	NCT02791334
Nivolumab	ant-mAb	PD-1	Anti-KIR mAb (Irilumab)	650	I/II	Jul. 2019	NCT01714739
Ipilimumab	ant-mAb	CTLA-4					
Durvalumab	ant-mAb	PD-L1	TGF- β Receptor I Kinase Inhibition (Galunisertib)	37	Ib	Apr. 2018	NCT02734160
Ipilimumab	ant-mAb	CTLA-4	Tyrosine kinase inhibitor (Imatinib)	96	I	Feb. 2020	NCT01738139
Pembrolizumab	ant-mAb	PD-1	Focal adhesion kinase (FAK) inhibition (Defactinib) Gemcitabine	50	I	Nov. 2017	NCT02546531
Durvalumab	ant-mAb	PD-L1	CSF-1R TKI (Pexidartinib)	58	I	Sep. 2018	NCT02777710
Pembrolizumab	ant-mAb	PD-1	Vitamin D Receptor Agonist Paricalcitol	24	II	Jun. 2019	NCT03331562
Ipilimumab	ant-mAb	CTLA-4	PARP inhibition (Niraparib)	84	Ib/II	Jan. 2021	NCT03404960
Nivolumab	ant-mAb	PD-1					

* Active, not recruiting; ant-mAb – antagonistic monoclonal antibody